Keros Therapeutics, Inc. (KROS) Stock Forecast
KROS analyst forecast
as of October 18, 2026- Analyst consensus
- Buy 4.14 / 5 from 7 analysts
- Price target
- $19.83 average of analyst targets
- Upside to target
- +86.1% from the latest close
- Next earnings
- November 4, 2026 EPS estimate $-0.96
- 52-week range
- $9.91 – $21.84
KROS analyst ratings
7 analystsNumber of analysts at each rating.
KROS price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
KROS earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.86 | −$1.53 | −$0.56 | −$0.18 | −377.8% | 4 |
| Current fiscal year (2026) | −$5.22 | −$5.90 | −$4.62 | $2.30 | −327.0% | 5 |
| Next fiscal year (2027) | −$6.62 | −$8.93 | −$3.84 | −$5.22 | −26.7% | 5 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
KROS revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $13.9M | $350,000 | $20.0M | −2.6% | 6 |
| Current fiscal year (2026) | $15.6M | $1.1M | $20.4M | −93.6% | 7 |
| Next fiscal year (2027) | $13.7M | $0 | $68.1M | −11.8% | 7 |
KROS EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
KROS revenue: reported and forecast
KROS EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$1.34 | −$1.30 | −$1.30 | −$0.79 | −$0.86 | −36.1% | 3 up · 1 down |
| Current fiscal year (2026) | −$5.23 | −$5.19 | −$5.19 | −$5.14 | −$5.22 | −0.1% | 3 up · 2 down |
| Next fiscal year (2027) | −$6.22 | −$5.59 | −$5.59 | −$6.61 | −$6.62 | +6.3% | 0 up · 6 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
KROS earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; KROS beat in 7 of 12.
What analysts expect from KROS
7 analysts cover Keros Therapeutics; their consensus rating is buy (4.14 on a 1–5 scale, where 5 is a strong buy). The average price target is $19.83, 86.1% above the latest close of $10.66. Analysts expect earnings of −$5.22 per share for 2026, −327.0% from a year earlier. For 2027 the average estimate is −$6.62 per share on revenue of $13.7 million. Keros Therapeutics beat the EPS estimate in 7 of the last 12 quarters.
Related: KROS income statement, KROS key metrics, KROS chart. See the KROS stock overview for the latest quote and news.
KROS forecast FAQ
What is Keros Therapeutics's price target?
The average analyst price target for Keros Therapeutics is $19.83, 86.1% above the latest close of $10.66.
Is Keros Therapeutics a buy, hold or sell?
Of 7 analysts covering Keros Therapeutics, 4 rate it a strong buy, 0 a buy, 3 a hold, 0 a sell and 0 a strong sell, a consensus of buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Keros Therapeutics's EPS forecast?
Analysts forecast −$5.22 per share for 2026 (range −$5.90 to −$4.62); for 2027 the estimate is −$6.62.
What is Keros Therapeutics's revenue forecast?
The average revenue estimate for 2026 is $15.6 million, growth of −93.6%; for 2027 it is $13.7 million.
When does Keros Therapeutics report earnings?
Keros Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 4, 2026 after the market closes; the EPS estimate is $-0.96.
Does Keros Therapeutics usually beat earnings estimates?
Keros Therapeutics reported EPS at or above the analyst estimate in 7 of the last 12 quarters.